Tyra Biosciences Advances Cancer Treatment with TYRA-200 and TYRA-300 Development Milestones

Tyra Biosciences, Inc. TYRA, a preclinical-stage biopharmaceutical company, has announced the administration of its first patient with TYRA-200 in the SURF201 Phase 1 study. This marks a substantial step forward in the clinical evaluation of their designed therapies to combat tumor resistance and enhance outcomes for cancer patients. The objective of this study is to assess the safety, tolerability, and early efficacy of TYRA-200 in patients.

Progress in SURF301 with TYRA-300

Concurrently, Tyra Biosciences provided an optimistic update on its SURF301 study, highlighting that several dose cohorts have been cleared and dose escalation continues with TYRA-300. This progress showcases the potential for TYRA-300 to move into later stages of clinical development.

Anticipated IND Submission for TYRA-300

In another positive stride, the company has received constructive feedback from the FDA on the TYRA-300 Phase 2 ACH (Advanced Cutaneous Hematologic malignancies) study. With this feedback, Tyra Biosciences is planning to submit an Investigational New Drug (IND) application in the second half of 2024. This submission will be pivotal to the commencement of the Phase 2 studies for TYRA-300, which exemplifies the company's commitment to propelling cancer treatments forward.

Tyra Biosciences, headquartered in Carlsbad, California, is dedicated to developing novel therapeutic strategies aimed at addressing the challenge of tumor resistance. The company's endeavours represent a beacon of hope in the ongoing fight against cancer, striving to bring forth solutions that may improve the lives of those afflicted by this disease.

Initiation, Trial, Oncology